Year: 2017
Type: dissertation
Abstract: Interleukin-12 (IL-12) is a pro-inflammatory cytokine that plays a major role in immune responses. IL-12 causes increases in T and NK cell proliferation, interferon-Îł (IFN- Îł) production and leads to a TH1 differentiation bias and cell-mediated immunity. Due to the many potent pro-inflammatory effects, the use of IL-12 for cancer immunotherapy has been a constant topic of debate. A promising approach to cancer immunotherapy has been studied by our lab where a small number of transduced tumour cells expressing IL-12 are injected to initiate an immune response. Upon injection, these IL-12 transduced host tumour cells cause sustained rejection, even to challenges with the original parent tumour. The effectiveness of this model has thus far been demonstrated in murine leukaemias and various solid tumour models. In this thesis, I have developed a novel breast cancer cell line model derived from the MMTV-PyMT transgenic breast cancer model to expand the cell-based IL-12 cancer immunotherapy into a more clinically relevant solid tumour model.
Source: TSpace (University of Toronto)
Author: Michael Mielnik
Institution: University of Toronto
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W2729929070
